Gaslightwala Abizer bought AKTX
March 20, 2025 · Form 4 insider transaction
Gaslightwala Abizer bought 600,000 shares of Akari Therapeutics, Plc at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Footnotes
The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock options shall vest upon achievement of at least one of the following performance criteria: either (a) closing of a qualified financing of at least $15,000,000 in gross proceeds on or before December 31, 2025, or (b) closing of an antibody drug conjugate ("ADC") focused license transaction, with a minimum upfront payment of $10,000,000 on or before December 31, 2025. If neither of these criteria are met by December 31, 2025 the performance-based option will expire. The stock option award is subject to continued service with the Issuer.; Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.